female scientist with a slide with a breast tumour

Quest to Partner with Paige.ai To Develop AI-Driven Digital Pathology Cancer Diagnostics

Memorial Sloan Kettering spin-out Paige will partner with Quest Diagnostics to develop precise AI-driven cancer assessment tools to speed up and improve diagnosis for patients with a range of solid tumors.
Antibodies responding to coronavirus particle, illustration

Antibody-Producing Cells Last at Least One Year After COVID-19 Infection

A new study finds that nearly a year after recovering from COVID-19, the body’s bone marrow plasma cells still make active antibodies against the virus. The findings appear to suggest that antibody production does not wane over time to the point of offering no protection.
Antibody proteins attacking coronavirus, illustration

Structural Details of How SARS-CoV-2 Variants Escape Immune Response Detailed in New Study

The researchers used structural biology to map, at atomic scale, how certain classes of neutralizing antibodies bind to the original pandemic strain of SARS-CoV-2, the virus that causes COVID-19.
Female doctor using otoscope on child

OSU Researchers Make Advances in Developing Gene Therapy to Allow the Deaf to Hear

The progress was made in the study of a gene responsible for an inner-ear protein, otoferlin. Mutations in otoferlin are linked to severe congenital hearing loss, a common type of deafness in which patients can hear almost nothing.

LDT Regulation Issue Rekindled with Reintroduction of VITAL Act

The VITAL Act would update federal lab standards under the Clinical Laboratory Improvement Amendments (CLIA), overseen by the U.S. Department of Health and Human Services (HHS)—through which LDTs would also be regulated under the Public Health Services Act, which gives HHS authority to respond to public health emergencies.
Antibodies responding to coronavirus particles, illustration

Memo Therapeutics’ Fast Technology Allows Targeting of Different SARS-CoV-2 Strains

Memo Therapeutics' candidate antibody shows good efficacy against SARS-CoV-2, including the U.K. variant. Using its technology, a new treatment can be developed within 3 weeks and the company aims to target all developing variant strains as part of an ongoing international collaboration.
Germany, Research laboratory, Young female scientist treating laboratory mouse

New Preclinical Model of HIV Will Aid in Drug Development

The cell-attacks-host problem found in prior mouse models is due to so-called “naïve” CD4 cells. When the researchers excluded naïve CD4 cells and instead used only “memory” CD4 cells, the cells survived indefinitely in the mice without causing major damage to their hosts.
Coronavirus spike protein and receptor, illustration

SARS-CoV-2 Reproductive Method Could Be Good Target for Therapies

High quality microscopy has captured mammalian translation of SARS-CoV-2 viral RNA in unprecedented detail. The virus uses a ‘pseudoknot’ structure to create tension in the ribosome and promote frameshifting to translate viral RNA.

Dual Approach to Treating Pancreatic Cancer Shows Promise

Australian researchers demonstrate that widening the fight against prostate cancer to include cancer-associated fibroblasts—cells that create fibrotic fortresses around pancreatic cancer tumors—may be an effective strategy against the disease.
Capsule with DNA inside

Two to Three Years Later, Gene Therapy Still Helping Patients with ADA-SCID

Forty-eight of 50 children who were provided a gene therapy for the immunodeficiency disease ADA-SCID retain replenished immune system function two to three years after receiving their treatment.


Scroll Up